{"gene":"HTR2C","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1995,"finding":"5-HT2C receptor-deficient (knockout) mice are overweight due to abnormal control of feeding behaviour, establishing a role for this receptor in serotonergic control of appetite; mutant animals also exhibit spontaneous death from seizures, implicating 5-HT2C receptors in tonic inhibition of neuronal network excitability.","method":"Targeted gene knockout mice with phenotypic readouts (body weight, food intake, seizure susceptibility)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple specific phenotypic readouts (obesity, epilepsy), widely replicated across subsequent studies","pmids":["7700379"],"is_preprint":false},{"year":1995,"finding":"A Cys23Ser substitution in the first hydrophobic region of the human 5-HT2C receptor (HTR2C on Xq24) was identified; when expressed in Xenopus oocytes, concentration-response curves to 5-HT were not significantly different between the two forms, indicating no functional difference under baseline conditions.","method":"SSCP analysis, linkage analysis, heterologous expression in Xenopus oocytes with electrophysiological recording","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — functional assay in Xenopus oocytes with electrophysiology; single lab, negative result reported","pmids":["7557992"],"is_preprint":false},{"year":1995,"finding":"Activation of 5-HT2C receptors stimulates APP ectodomain (APPs) secretion via a mechanism requiring both PKC and phospholipase A2 (PLA2), as demonstrated in 3T3 cells stably overexpressing 5-HT2cR; this is distinct from 5-HT2A receptor coupling, which requires PLA2 but not PKC.","method":"Stable cell line overexpression, pharmacological inhibitors of PKC and PLA2, APPs secretion assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with pharmacological dissection; single lab, two orthogonal inhibitor approaches","pmids":["8626761"],"is_preprint":false},{"year":1995,"finding":"Activation of 5-HT2C receptor in choroid plexus triggers cyclic GMP (cGMP) formation in a calcium-, phospholipase A2-, and lipoxygenase-dependent manner, in addition to phosphoinositide turnover.","method":"Porcine choroid plexus tissue slices, pharmacological antagonists, cGMP assay, pertussis toxin pretreatment, PLA2 and lipoxygenase inhibitors","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo tissue preparation with pharmacological dissection; single lab, multiple inhibitor conditions","pmids":["7798914"],"is_preprint":false},{"year":1996,"finding":"The human 5-HT2C receptor gene (HTR2C) contains six exons and five introns spanning at least 230 kb; an alternatively spliced isoform with a 95-nt deletion in the region coding for the second intracellular loop produces a truncated 248-aa protein. Transcription initiates at multiple sites with no classical TATA box.","method":"Genomic cloning, cDNA isolation, sequencing, RT-PCR, luciferase reporter assay","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization; single lab, multiple orthogonal molecular methods","pmids":["8812491"],"is_preprint":false},{"year":1996,"finding":"Fluoxetine and other SSRIs (norfluoxetine, citalopram) act as antagonists at the 5-HT2C receptor, inhibiting 5-HT-stimulated phosphoinositide hydrolysis without inverse agonist activity, as demonstrated in choroid plexus and clonal cell lines expressing the cloned rat 5-HT2C receptor.","method":"Radioligand binding ([3H]mesulergine), phosphoinositide (PI) hydrolysis assay, cloned receptor cell lines and rat choroid plexus","journal":"Psychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional PI hydrolysis assay combined with radioligand binding; single lab, two orthogonal methods","pmids":["8876023"],"is_preprint":false},{"year":1998,"finding":"RNA editing of the 5-HT2C receptor at four major adenosine-to-inosine positions (A, B, C, D) in the second intracellular loop alters receptor isoforms' ability to interact with the phospholipase C signaling cascade; editing is mediated by at least two members of the ADAR family and requires an extensive RNA duplex structure formed by exonic and intronic sequences of 5-HT2C pre-mRNA.","method":"In vitro transcription, ADAR family enzyme assays, transfected cell line functional assays (phospholipase C coupling), structural analysis of RNA duplex","journal":"Annals of the New York Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro editing assays with functional validation; replicated across multiple subsequent studies","pmids":["9928237"],"is_preprint":false},{"year":1997,"finding":"Site-directed mutagenesis of serine 312 to phenylalanine (S312F) or lysine (S312K) in the 5-HT2C receptor creates constitutively active receptors that spontaneously couple to G proteins and stimulate phosphatidylinositol hydrolysis in the absence of agonist; mianserin and mesulergine act as inverse agonists on the S312K mutant receptor.","method":"Site-directed mutagenesis, COS-7 cell expression, [3H]mesulergine and [3H]5-HT radioligand binding, PI hydrolysis assay, GppNHp treatment","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution via site-directed mutagenesis with functional validation of constitutive activity and inverse agonism; rigorous single study with multiple assays","pmids":["9282936"],"is_preprint":false},{"year":1999,"finding":"RNA editing of the 5-HT2C receptor decreases receptor basal (constitutive) activity, agonist affinity, and agonist potency for inositol phosphate production. The non-edited isoform (INI) shows fourfold greater basal IP production than the fully edited isoform (VGV); 5-HT competes for two binding sites on INI but only one site on VGV.","method":"COS-7 cell transient expression, inositol phosphate assay, radioligand binding ([3H]mesulergine, [3H]5-HT), dose-response analysis","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro functional reconstitution with multiple receptor isoforms, multiple assay endpoints; replicated by subsequent studies","pmids":["10501219"],"is_preprint":false},{"year":1999,"finding":"RNA editing of the human 5-HT2C receptor at five sites (including a novel 5th site) reduces agonist binding affinity and functional potency in proportion to agonist intrinsic activity; full agonists are most affected and antagonists are unaffected, suggesting editing alters coupling energetics within the ternary complex.","method":"Analysis of human brain/hypothalamic RNA, cloning of isoforms, radioligand binding and functional assays in recombinant receptor systems","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct functional characterization of multiple human receptor isoforms with binding and functional assays; replicated finding","pmids":["10432493"],"is_preprint":false},{"year":1999,"finding":"Prolonged treatment (24 h) with inverse agonists at human 5-HT2C receptors selectively enhances 5-HT2C-mediated inositol phosphate (IP) accumulation but not arachidonic acid (AA) release; this enhanced responsiveness is not due to receptor up-regulation but may involve changes in expression of Gαq/11 and possibly Gα12/Gα13.","method":"CHO cells stably expressing human 5-HT2C receptor, IP accumulation assay, AA release assay, pharmacological dissection with neutral antagonists and agonists","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable cell line functional assays with multiple ligand conditions; single lab, two orthogonal signaling readouts","pmids":["10220565"],"is_preprint":false},{"year":1999,"finding":"LSD signals differently from serotonin (5-HT) at the 5-HT2C receptor; specifically, RNA editing of the 5-HT2C receptor dramatically alters the ability of LSD to stimulate phosphatidylinositol signaling, demonstrating agonist-directed trafficking at this receptor.","method":"Cell-based phosphatidylinositol signaling assay with edited and non-edited receptor isoforms, comparison of LSD vs. 5-HT efficacy","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based assay with multiple isoforms; single lab, limited methodological detail in abstract","pmids":["10432492"],"is_preprint":false},{"year":1998,"finding":"5-HT2C receptors in the hippocampal formation are required for normal long-term potentiation specifically at medial perforant path-dentate gyrus synapses; 5-HT2C receptor null mutant mice show selective LTP impairment at this synapse accompanied by abnormal Morris water maze performance and reduced novelty aversion.","method":"5-HT2C receptor knockout mice, electrophysiological LTP recording at four hippocampal pathways, Morris water maze behavioral testing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with targeted electrophysiological readout at specific synapse plus behavioral validation; multiple orthogonal methods","pmids":["9844009"],"is_preprint":false},{"year":2000,"finding":"5-HT2C receptor protein is expressed on neuronal cell bodies throughout the CNS, including hippocampus, amygdala, thalamus, caudate-putamen, cortex, and dorsal raphé nuclei, consistent with postsynaptic localization to serotonergic neurons and possible autoreceptor function in raphé.","method":"Immunohistochemistry with polyclonal antibodies against rat 5-HT2C receptor protein, Western blot, immunofluorescence in transfected HEK293 cells, peptide competition controls","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunohistochemistry with antibody validation (Western blot, peptide competition, transfected cell controls); single lab","pmids":["10665825"],"is_preprint":false},{"year":2004,"finding":"The 5-HT2C receptor C-terminus (PDZ ligand SXV) interacts with a specific set of PDZ proteins distinct from those binding the 5-HT2A receptor: 5-HT2C binds the Veli-3·CASK·Mint1 ternary complex, SAP102, PSD-95, and MPP-3; residues at the -1 position and upstream of the PDZ ligand determine partner specificity. These interactions occur in intracellular compartments in living cells.","method":"Affinity chromatography with immobilized synthetic PDZ ligand peptides, mass spectrometry, co-immunoprecipitation, immunofluorescence, electron microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — proteomic affinity chromatography plus MS identification, confirmed by co-IP and cellular imaging; multiple orthogonal methods in single study","pmids":["14988405"],"is_preprint":false},{"year":2004,"finding":"RNA editing of the human 5-HT2C receptor modulates splice site selection; editing at multiple sites in a stable stem-loop encompassing the normal and alternative 5' splice sites of intron 5 profoundly alters relative splicing at normal versus alternative upstream splice sites, linking A-to-I editing to control of pre-mRNA splicing.","method":"In vitro editing, cell culture base-substitution experiments, human brain splice variant analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro editing reconstitution combined with cell culture mutational analysis and human brain validation; multiple orthogonal methods","pmids":["15087490"],"is_preprint":false},{"year":2004,"finding":"RNA editing at the non-edited (INI) 5-HT2C receptor isoform activates phospholipase D via the G13 heterotrimer G-protein, requiring transactivation of the small G-protein RhoA; the fully edited VGV isoform does not activate RhoA or phospholipase D, demonstrating that editing regulates signaling pathway selection including pathways linked to actin cytoskeletal organization.","method":"Transfected cell lines expressing INI vs. VGV isoforms, phospholipase D activity assay, RhoA activation assay, pharmacological G-protein inhibitors","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro functional reconstitution with isoform comparison, multiple signaling pathway assays, and mechanistic dissection; single rigorous study","pmids":["14722258"],"is_preprint":false},{"year":2004,"finding":"5-HT2C receptors exist as constitutive homodimers on the plasma membrane of living cells, demonstrated by immunoprecipitation/Western blot showing monomer and dimer bands, BRET (Renilla luciferase/YFP), and confocal FRET (CFP/YFP donor-acceptor pairs) on the plasma membrane; BRET levels were not altered by serotonin pretreatment, indicating constitutive (agonist-independent) dimerization.","method":"Immunoprecipitation, Western blot, BRET in HEK293 cells, confocal FRET by acceptor photobleaching","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — three independent biophysical methods (IP/WB, BRET, FRET) all demonstrating homodimerization in living cells; rigorous single study","pmids":["15518545"],"is_preprint":false},{"year":2004,"finding":"Interferon-alpha (IFN-α) rapidly alters ADAR1 expression and the pattern of 5-HT2C receptor mRNA editing in human glioblastoma cells, leading to dominant expression of the 5-HT2C-VSI isoform predicted to have reduced G-protein coupling functions.","method":"Human glioblastoma cell line treatment with IFN-α, RT-PCR analysis of editing patterns, ADAR1 expression analysis","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based experiment with direct measurement of editing changes; single lab, limited mechanistic follow-up in abstract","pmids":["15093687"],"is_preprint":false},{"year":2005,"finding":"5-HT2C receptor couples to ERK1/2 via a pathway requiring phospholipase D, protein kinase C, and the Raf/MEK/ERK module, but independent of receptor and non-receptor tyrosine kinases, PLC, PI3K, and endocytosis; agonist-directed trafficking was observed whereby DOI and quipazine showed reversal of efficacy between PI/Ca2+ pathways and ERK1/2 phosphorylation.","method":"CHO cells stably expressing non-edited 5-HT2C receptor, ERK1/2 phosphorylation assay, pharmacological inhibitors of multiple signaling intermediates","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic pharmacological dissection of signaling pathway with multiple inhibitors and multiple readouts in a defined cell system; single rigorous study","pmids":["15935077"],"is_preprint":false},{"year":2003,"finding":"PNU-69176E acts as a positive allosteric modulator (PAM) of the human 5-HT2C receptor; at low micromolar concentrations it markedly enhances [3H]5-HT binding (>300%) by increasing agonist affinity without affecting antagonist binding ([3H]mesulergine), and renders receptors constitutively active (GTPγS binding, IP3 release, IP accumulation). This selectivity is for 5-HT2C over 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, D2L, and D3 receptors.","method":"Radioligand binding, GTPγS binding, IP3 measurement, IP accumulation assay across multiple cell lines and receptor types; structure-activity relationship of alkyl chain length","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with multiple functional endpoints, receptor selectivity panel, and SAR; single rigorous study","pmids":["12815163"],"is_preprint":false},{"year":2007,"finding":"5-HT2C receptor agonism produces hypophagia downstream via activation of melanocortin 4 receptors (MC4R); 5-HT2CRs are coexpressed with POMC neurons in the arcuate nucleus, and mice lacking MC4R are not responsive to 5-HT2CR agonist-induced hypophagia, establishing that melanocortins acting on MC4R are a requisite downstream pathway.","method":"Coexpression studies (5-HT2CR/POMC), chronic BVT.X infusion in obese mice measuring Pomc mRNA and body weight, genetic epistasis using MC4R knockout mice","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (MC4R KO) combined with neuroanatomical coexpression and Pomc mRNA measurement; multiple orthogonal approaches","pmids":["18039773"],"is_preprint":false},{"year":1998,"finding":"5-HT2C and 5-HT2A receptors exhibit agonist-directed trafficking of receptor stimulus: relative efficacies of agonists differ depending on whether phospholipase C-mediated IP accumulation or PLA2-mediated arachidonic acid release is measured, demonstrating that different agonists selectively activate subsets of multiple signaling pathways coupled to a single receptor.","method":"Cell-based assays measuring IP accumulation and arachidonic acid release with multiple agonists; relative efficacy referenced to 5-HT","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based assays with multiple agonists and two parallel signaling readouts; single lab","pmids":["9928246"],"is_preprint":false},{"year":2009,"finding":"Loss of the imprinted snoRNA mbii-52 (h/mbii-52) in a mouse model of Prader-Willi syndrome leads to increased A-to-I editing of the 5-HT2C receptor (5htr2c) pre-RNA, establishing that mbii-52 negatively regulates 5htr2c editing in vivo; increased editing is associated with alterations in 5-HT2CR-related behaviours (impulsive responding, locomotor activity, food reactivity) confirmed by pharmacological challenge.","method":"PWS-IC+/- mouse model, quantitative editing analysis, behavioral testing with pharmacological (5-HT2CR drug challenge) confirmation of mechanism","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function model with direct measurement of editing changes, multiple behavioral readouts, and pharmacological confirmation of 5-HT2CR specificity","pmids":["19304781"],"is_preprint":false},{"year":2010,"finding":"5-HT2C receptor antagonism within the orbitofrontal cortex (OFC), but not the medial prefrontal cortex or nucleus accumbens, improves spatial reversal learning by reducing perseverative errors, establishing a neuroanatomically specific role for OFC 5-HT2C receptors in cognitive flexibility.","method":"Site-specific intracerebral microinfusion of selective 5-HT2C antagonist SB 242084 into OFC, mPFC, or NAc; spatial reversal learning behavioral paradigm","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — targeted intracerebral infusion with specific behavioral readout; single lab, dose-response within OFC","pmids":["20089901"],"is_preprint":false},{"year":2010,"finding":"After spinal cord injury, 5-HT2B and 5-HT2C receptors on motoneurons become constitutively active and facilitate persistent calcium currents (Ca PICs) and long-lasting reflexes (muscle spasms); inverse agonists blocking constitutive 5-HT2C/2B activity reduce spasms, while neutral antagonists (which do not block constitutive activity) have no effect alone.","method":"Chronic spinal rat in vitro preparation, ventral root recording of long-lasting reflexes, intracellular recording of Ca PICs, selective agonists/antagonists/inverse agonists, immunolabeling of 5-HT2B/2C on motoneurons","journal":"Journal of neurophysiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological dissection distinguishing agonist, neutral antagonist, and inverse agonist effects; confirmed by immunolabeling; clean constitutive activity demonstration in vivo","pmids":["20980537"],"is_preprint":false},{"year":2012,"finding":"5-HT2C receptor activation in hypothalamic POMC neurons inhibits the M-current (KCNQ channel-mediated) by 34–42%, increasing neuronal excitability; the selective 5-HT2C antagonist RS-102221 abrogates this effect, establishing 5-HT2C-mediated inhibition of M-current as a mechanism for serotonin-induced POMC activation and reduced food intake.","method":"Visualized-patch clamp recording in eGFP-POMC transgenic mouse hypothalamic neurons, selective pharmacological agonists/antagonists (DOI, mCPP, RS-102221), KCNQ blocker XE-991","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct electrophysiology in identified neurons with selective pharmacological validation; multiple agonists and antagonist confirmation","pmids":["22436698"],"is_preprint":false},{"year":2015,"finding":"Melatonin MT2 and 5-HT2C receptors form functional heteromers both in transfected cells and in human cortex and hippocampus; MT2/5-HT2C heteromers amplify 5-HT-mediated Gq/PLC response and enable melatonin-induced unidirectional transactivation of the 5-HT2C protomer; the antidepressant agomelatine shows biased signaling at these heteromers.","method":"Co-immunoprecipitation, bioluminescence resonance energy transfer (BRET), pharmacological assays in transfected cells and human brain tissue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — three independent methods (co-IP, BRET, pharmacology) demonstrating heteromer formation with functional consequences; validated in human brain tissue","pmids":["25770211"],"is_preprint":false},{"year":2018,"finding":"SSRIs impair motor function through 5-HT2C receptors in the substantia nigra pars reticulata (SNr), which inhibit dopaminergic neurons in the substantia nigra pars compacta (SNc); SSRI-induced SNr hyperactivity and SNc hypoactivity are reversed by systemic or SNr-localized 5-HT2C receptor antagonism; optogenetic inhibition of SNc neurons mimics SSRI motor deficits and 5-HT2C antagonism or optogenetic SNc activation reverses them.","method":"Mouse model with systemic SSRIs, localized SNr 5-HT2C receptor antagonism, optogenetic activation/inhibition of SNc dopaminergic neurons, motor function behavioral assays","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological circuit dissection combined with optogenetics and site-specific antagonism; multiple orthogonal methods establishing SNr 5-HT2C → SNc DA pathway","pmids":["30120415"],"is_preprint":false},{"year":2002,"finding":"5-HT2C receptor null mutant mice show more wakefulness, abnormalities in REM sleep expression, and enhanced response to sleep deprivation compared to wild-type mice, establishing a role for 5-HT2C receptors in sleep expression and sleep homeostasis.","method":"5-HT2C receptor knockout mice, polysomnographic sleep recording, sleep deprivation protocol","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with quantitative sleep recording; multiple sleep stage phenotypes","pmids":["12431861"],"is_preprint":false},{"year":2007,"finding":"5-HT2C receptor promoter polymorphisms (-759C/T and -697G/C) alter promoter activity in SH-SY5Y neuroblastoma cells; the -759T and -697C alleles reduce promoter activity, and the haplotype associated with resistance to antipsychotic-induced weight gain shows reduced activity compared to the most common haplotype.","method":"Luciferase reporter constructs with four promoter haplotypes transfected into SH-SY5Y cells, in presence or absence of constitutively active 5-HT2C receptor","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional promoter assay with multiple haplotypes; single lab","pmids":["17376412"],"is_preprint":false},{"year":2019,"finding":"In the lateral habenula (LHb), 5-HT2C receptor levels and 5-HIAA/5-HT ratio are increased in alcohol-withdrawn rats; intra-LHb 5-HT2C receptor antagonism (SB242084) alleviates anxiety-like behaviors and reduces elevated c-Fos expression, and increases KCNQ2/3 membrane protein expression in LHb, establishing that enhanced LHb 5-HT2C receptor signaling interacts with M-channels to trigger withdrawal anxiety.","method":"Intra-LHb microinfusion of SB242084 or WAY161503, elevated plus-maze, open-field, marble-burying tests, c-Fos immunohistochemistry, Western blot of KCNQ2/3 and 5-HT2C protein","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-specific pharmacological manipulation with multiple behavioral and molecular readouts; single lab","pmids":["31778691"],"is_preprint":false},{"year":2022,"finding":"In iPSC-derived GABAergic interneurons from patients with major depressive disorder with suicide behavior (sMDD), 5-HT2C receptor expression is decreased and neuronal activity is abnormal (increased firing, weakened calcium signaling); pharmacological agonism or genetic restoration of 5-HT2C receptor rescues neuronal activity deficits, establishing 5-HT2C as a mechanistic determinant of interneuron dysfunction in sMDD.","method":"iPSC-derived GABAergic interneurons and ventral forebrain organoids from sMDD patients, transcriptomic sequencing, calcium imaging, electrophysiology, pharmacological and genetic 5-HT2C receptor manipulation","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human iPSC loss-of-function model with multiple functional readouts and rescue experiments; single lab","pmids":["36373384"],"is_preprint":false}],"current_model":"HTR2C (5-HT2C receptor) is a constitutively active, class A GPCR that couples primarily to Gq/11 to activate phospholipase C (IP production), and additionally to G13/RhoA to activate phospholipase D, as well as to PLA2-cGMP and ERK1/2 pathways via PKC and Raf/MEK; its signaling is profoundly regulated by A-to-I RNA editing of up to five sites in the second intracellular loop (controlled by ADAR enzymes and negatively regulated by snoRNA mbii-52), which reduces constitutive activity, agonist affinity and G-protein coupling efficiency, and also modulates splice site selection; the receptor forms constitutive homodimers and functional heteromers with melatonin MT2 receptors on the plasma membrane; it interacts via its C-terminal PDZ ligand with scaffolding proteins including PSD-95, SAP102, and the Veli-3·CASK·Mint1 complex; in the hypothalamus it is co-expressed with POMC neurons where it suppresses the M-current to increase neuronal excitability and drives hypophagia downstream through melanocortin 4 receptors; in the substantia nigra pars reticulata 5-HT2C receptor activation inhibits SNc dopaminergic neurons; and in motoneurons after spinal cord injury the receptor becomes constitutively active to facilitate persistent calcium currents and muscle spasms."},"narrative":{"mechanistic_narrative":"HTR2C encodes the serotonin 5-HT2C receptor, a constitutively active class A GPCR that governs serotonergic control of appetite, neuronal network excitability, sleep, and cognitive flexibility, as established genetically by knockout mice that become obese and die from spontaneous seizures [PMID:7700379, PMID:12431861]. The receptor couples through multiple signaling routes: it activates phospholipase C-driven inositol phosphate production [PMID:10501219], engages a G13/RhoA-dependent phospholipase D pathway [PMID:14722258], and drives ERK1/2 phosphorylation via PLD, PKC, and the Raf/MEK module [PMID:15935077], with agonists showing biased efficacy across these PLC, PLA2, and ERK outputs (agonist-directed trafficking) [PMID:10432492, PMID:9928246]. Receptor activity is intrinsically constitutive, demonstrated by activating mutations at serine 312 that confer agonist-independent G-protein coupling and reveal inverse agonism by ligands such as mianserin [PMID:9282936]. A defining regulatory feature is A-to-I RNA editing at up to five sites in the second intracellular loop, mediated by ADAR enzymes acting on an exon-intron RNA duplex; editing reduces basal activity, agonist affinity, and coupling efficiency (non-edited INI vs. fully edited VGV isoforms) and selects which downstream pathways the receptor engages, and the same stem-loop links editing to alternative splice-site choice [PMID:9928237, PMID:10501219, PMID:10432493, PMID:15087490, PMID:14722258]. This editing is constrained in vivo by the imprinted snoRNA mbii-52 and is modulated by interferon-alpha via ADAR1 [PMID:19304781, PMID:15093687]. The receptor's C-terminal PDZ ligand recruits scaffolding proteins including PSD-95, SAP102, MPP-3, and the Veli-3·CASK·Mint1 complex [PMID:14988405], and it forms constitutive homodimers and functional heteromers with the melatonin MT2 receptor that amplify Gq/PLC signaling and permit transactivation [PMID:15518545, PMID:25770211]. In hypothalamic POMC neurons it inhibits the KCNQ-mediated M-current to raise excitability and produces hypophagia that requires downstream melanocortin MC4 receptors [PMID:22436698, PMID:18039773]. Circuit-level studies place 5-HT2C in the substantia nigra pars reticulata, where activation inhibits SNc dopaminergic neurons and underlies SSRI-induced motor deficits [PMID:30120415], and in spinal motoneurons, where injury renders the receptor constitutively active to drive persistent calcium currents and muscle spasms reversible by inverse agonists [PMID:20980537].","teleology":[{"year":1995,"claim":"Establishing the physiological role of 5-HT2C addressed whether this receptor controls organismal feeding and network excitability rather than acting as a redundant serotonin receptor.","evidence":"Targeted knockout mice scored for body weight, food intake, and seizure susceptibility","pmids":["7700379"],"confidence":"High","gaps":["Does not identify the cell types or circuits mediating appetite vs. seizure phenotypes","Mechanism linking receptor loss to network hyperexcitability unresolved at the molecular level"]},{"year":1995,"claim":"Early functional and structural characterization defined the receptor's signaling outputs beyond simple phosphoinositide turnover and its gene architecture.","evidence":"Choroid plexus tissue assays for cGMP/PI turnover, 3T3 cell APPs secretion with PKC/PLA2 inhibitors, and genomic cloning of the six-exon gene with an alternatively spliced isoform","pmids":["7798914","8626761","8812491"],"confidence":"Medium","gaps":["The physiological relevance of cGMP and APPs outputs in neurons was not established","Functional consequence of the truncated splice isoform not determined"]},{"year":1997,"claim":"Demonstrating that point mutations at serine 312 produce agonist-independent coupling answered whether 5-HT2C possesses intrinsic constitutive activity and whether ligands can act as inverse agonists.","evidence":"Site-directed mutagenesis (S312F/S312K) in COS-7 cells with radioligand binding and PI hydrolysis assays","pmids":["9282936"],"confidence":"High","gaps":["Whether wild-type receptor shows comparable constitutive activity in native tissue was not addressed here","Structural basis of the conformational switch not resolved"]},{"year":1998,"claim":"Discovery of A-to-I RNA editing in the second intracellular loop answered how a single gene generates functionally distinct receptor isoforms.","evidence":"In vitro ADAR editing assays with RNA duplex structural analysis and PLC coupling assays of edited isoforms","pmids":["9928237"],"confidence":"High","gaps":["Tissue- and disease-specific editing patterns not yet quantified","Relative contribution of individual ADAR family members not separated"]},{"year":1998,"claim":"Documenting differential agonist efficacy across PLC versus PLA2 readouts established that a single receptor activates distinct signaling subsets (agonist-directed trafficking).","evidence":"Cell-based IP accumulation and arachidonic acid release assays with multiple agonists","pmids":["9928246"],"confidence":"Medium","gaps":["Molecular basis of biased coupling (distinct receptor conformations vs. G-protein availability) not resolved"]},{"year":1999,"claim":"Quantitative isoform comparison established that editing tunes receptor pharmacology, reducing basal activity, agonist affinity, and coupling in proportion to agonist efficacy.","evidence":"COS-7 expression of INI vs. VGV and multi-site human isoforms with IP and radioligand binding assays, including LSD versus 5-HT trafficking","pmids":["10501219","10432493","10432492"],"confidence":"High","gaps":["In vivo editing ratios across brain regions and their behavioral impact not yet linked","Energetic model of ternary-complex alteration inferred rather than structurally demonstrated"]},{"year":1999,"claim":"Chronic inverse agonist studies probed how constitutive activity adapts, showing pathway-selective sensitization of IP but not arachidonic acid signaling.","evidence":"CHO cells stably expressing human 5-HT2C with IP and AA release assays under chronic ligand treatment","pmids":["10220565"],"confidence":"Medium","gaps":["Direct evidence for Galpha subunit expression changes was inferential","Relevance to chronic drug treatment in vivo not tested"]},{"year":2002,"claim":"Sleep phenotyping of knockout mice extended the receptor's physiological role to sleep expression and homeostasis.","evidence":"Polysomnographic recording in 5-HT2C null mice with sleep deprivation challenge","pmids":["12431861"],"confidence":"High","gaps":["Circuit and signaling mechanisms underlying altered wakefulness not identified"]},{"year":2003,"claim":"Identification of a selective positive allosteric modulator answered whether 5-HT2C affinity and constitutive activity could be pharmacologically enhanced from an allosteric site.","evidence":"Radioligand binding, GTPgammaS, IP3, and IP assays across a receptor selectivity panel with SAR analysis of PNU-69176E","pmids":["12815163"],"confidence":"High","gaps":["Allosteric binding site location not mapped","In vivo efficacy of the PAM not established"]},{"year":2004,"claim":"Defining the C-terminal PDZ interactome and homodimerization established how the receptor is scaffolded and organized at the membrane.","evidence":"Affinity chromatography/MS, co-IP, and imaging for PDZ partners; IP/WB, BRET, and FRET for constitutive homodimers","pmids":["14988405","15518545"],"confidence":"High","gaps":["Functional consequences of each scaffold interaction for signaling/trafficking not dissected","Whether dimerization affects coupling efficiency not tested"]},{"year":2004,"claim":"Mechanistic studies connected editing to both pathway selection and splicing, showing editing controls G13/RhoA/PLD coupling and intron 5 splice-site choice.","evidence":"Isoform-specific PLD and RhoA assays with G-protein inhibitors; in vitro editing plus base-substitution splicing analysis with human brain validation; IFN-alpha modulation of ADAR1/editing in glioblastoma cells","pmids":["14722258","15087490","15093687"],"confidence":"High","gaps":["In vivo coupling between editing-driven splicing and receptor function not quantified","Physiological triggers of IFN-alpha-mediated editing changes in brain unclear"]},{"year":2005,"claim":"Pathway dissection of ERK1/2 activation defined a PLD/PKC/Raf-MEK route independent of tyrosine kinases, PLC, and endocytosis, reinforcing biased signaling.","evidence":"ERK1/2 phosphorylation assays in CHO cells with a panel of pathway inhibitors and divergent agonists","pmids":["15935077"],"confidence":"High","gaps":["Downstream transcriptional/cellular consequences of ERK activation not addressed","Endogenous neuronal validation absent"]},{"year":2007,"claim":"Genetic epistasis established the downstream circuit for hypophagia, placing MC4R-expressing melanocortin signaling as a requisite effector of 5-HT2C anorectic action.","evidence":"POMC coexpression studies, chronic agonist infusion in obese mice, and MC4R knockout epistasis; plus promoter haplotype reporter assays linking polymorphisms to weight-gain susceptibility","pmids":["18039773","17376412"],"confidence":"High","gaps":["Promoter polymorphism findings (Medium) await in vivo validation","Exact synaptic relationship between 5-HT2C+ neurons and POMC/MC4R circuit not fully mapped"]},{"year":2009,"claim":"Identifying snoRNA mbii-52 as a negative regulator of editing established an in vivo control point linking the Prader-Willi locus to 5-HT2C function.","evidence":"PWS-IC+/- mouse model with quantitative editing analysis and pharmacologically confirmed behavioral readouts","pmids":["19304781"],"confidence":"High","gaps":["Molecular mechanism by which mbii-52 suppresses editing not defined","Contribution to the full Prader-Willi phenotype not isolated"]},{"year":2010,"claim":"Region-specific pharmacological manipulation localized cognitive-flexibility and spinal motor roles, distinguishing where the receptor exerts behavioral and constitutive-activity effects.","evidence":"Intra-OFC antagonist microinfusion in a reversal-learning task; chronic spinal rat preparation distinguishing agonist, neutral antagonist, and inverse agonist effects on Ca PICs and reflexes","pmids":["20089901","20980537"],"confidence":"High","gaps":["Cellular signaling underlying OFC behavioral effect not defined","How spinal injury triggers acquired constitutive activity is unknown"]},{"year":2012,"claim":"Direct electrophysiology in identified POMC neurons established M-current (KCNQ) inhibition as the ionic mechanism by which 5-HT2C raises excitability to suppress feeding.","evidence":"Visualized patch-clamp in eGFP-POMC neurons with selective agonists/antagonists and KCNQ blockade","pmids":["22436698"],"confidence":"High","gaps":["Signaling intermediates linking receptor to KCNQ channel closure not delineated"]},{"year":2015,"claim":"Demonstration of MT2/5-HT2C heteromers in human brain established a cross-receptor signaling module relevant to antidepressant action.","evidence":"Co-IP, BRET, and pharmacology in transfected cells and human cortex/hippocampus, including agomelatine bias","pmids":["25770211"],"confidence":"High","gaps":["Physiological and behavioral significance of the heteromer in vivo not established","Stoichiometry and structural arrangement unknown"]},{"year":2018,"claim":"Circuit dissection placed SNr 5-HT2C upstream of SNc dopaminergic inhibition, explaining SSRI-induced motor deficits.","evidence":"SSRI treatment with site-specific SNr antagonism and optogenetic manipulation of SNc neurons in mice","pmids":["30120415"],"confidence":"High","gaps":["Cell-autonomous signaling of SNr 5-HT2C not resolved","Editing/isoform contribution to this circuit not examined"]},{"year":2019,"claim":"Lateral habenula studies extended the receptor-M-channel relationship to a withdrawal-anxiety circuit.","evidence":"Intra-LHb antagonist/agonist microinfusion with behavioral tests, c-Fos, and KCNQ2/3 Western blot in alcohol-withdrawn rats","pmids":["31778691"],"confidence":"Medium","gaps":["Single-lab pharmacological study without genetic confirmation","Direct electrophysiological link to M-current in LHb not measured"]},{"year":2022,"claim":"Human iPSC modeling connected reduced 5-HT2C expression to GABAergic interneuron dysfunction in suicidal depression, with rescue establishing causality.","evidence":"iPSC-derived interneurons and organoids from sMDD patients with calcium imaging, electrophysiology, and pharmacological/genetic 5-HT2C restoration","pmids":["36373384"],"confidence":"Medium","gaps":["Single-lab human model not replicated","Mechanism linking receptor loss to altered firing/calcium signaling not defined"]},{"year":null,"claim":"How RNA-editing-defined isoforms, biased signaling, dimerization/heteromerization, and scaffolding are integrated within specific neuronal circuits to produce distinct behavioral outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of edited vs. unedited receptor coupling states","Causal in vivo role of MT2 heteromers and PDZ scaffolds not established","Mechanism of acquired constitutive activity after spinal injury unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,8,16,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[17,25,26,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,16,19]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[12,26,28]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[6,9,15,23]}],"complexes":["MT2/5-HT2C receptor heteromer","5-HT2C receptor homodimer","Veli-3·CASK·Mint1 complex"],"partners":["MTNR1B","DLG4","DLG3","CASK","APBA1","ADAR","ADAR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28335","full_name":"5-hydroxytryptamine receptor 2C","aliases":["5-hydroxytryptamine receptor 1C","5-HT-1C","5-HT1C","Serotonin receptor 2C"],"length_aa":458,"mass_kda":51.8,"function":"G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:12970106, PubMed:18703043, PubMed:19057895, PubMed:29398112, PubMed:7895773). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) (PubMed:19057895, PubMed:29398112). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:18703043, PubMed:29398112). HTR2C is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively (PubMed:18703043, PubMed:29398112). Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:29398112). Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelanocortin neurons and the release of CRH that then regulates the release of corticosterone (By similarity). Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress (By similarity). Plays a role in insulin sensitivity and glucose homeostasis (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P28335/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HTR2C","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HTR2C","total_profiled":1310},"omim":[{"mim_id":"612679","title":"CUGBP- AND ELAV-LIKE FAMILY, MEMBER 4; CELF4","url":"https://www.omim.org/entry/612679"},{"mim_id":"609837","title":"SMALL NUCLEOLAR RNA, C/D BOX, 115-1; SNORD115-1","url":"https://www.omim.org/entry/609837"},{"mim_id":"608516","title":"MAJOR DEPRESSIVE DISORDER; MDD","url":"https://www.omim.org/entry/608516"},{"mim_id":"607834","title":"ANXIETY","url":"https://www.omim.org/entry/607834"},{"mim_id":"605187","title":"G PROTEIN-COUPLED RECEPTOR 27; GPR27","url":"https://www.omim.org/entry/605187"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":28.2},{"tissue":"choroid plexus","ntpm":104.4}],"url":"https://www.proteinatlas.org/search/HTR2C"},"hgnc":{"alias_symbol":["5-HT2C","5HTR2C"],"prev_symbol":["HTR1C"]},"alphafold":{"accession":"P28335","domains":[{"cath_id":"1.20.1070.10","chopping":"60-253_302-385","consensus_level":"medium","plddt":91.5099,"start":60,"end":385}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28335","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28335-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28335-F1-predicted_aligned_error_v6.png","plddt_mean":73.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HTR2C","jax_strain_url":"https://www.jax.org/strain/search?query=HTR2C"},"sequence":{"accession":"P28335","fasta_url":"https://rest.uniprot.org/uniprotkb/P28335.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28335/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28335"}},"corpus_meta":[{"pmid":"7700379","id":"PMC_7700379","title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7700379","citation_count":1038,"is_preprint":false},{"pmid":"9225286","id":"PMC_9225286","title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.","date":"1997","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9225286","citation_count":458,"is_preprint":false},{"pmid":"10665825","id":"PMC_10665825","title":"Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS.","date":"2000","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10665825","citation_count":300,"is_preprint":false},{"pmid":"9694950","id":"PMC_9694950","title":"5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.","date":"1998","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9694950","citation_count":258,"is_preprint":false},{"pmid":"16433010","id":"PMC_16433010","title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies.","date":"2005","source":"Therapie","url":"https://pubmed.ncbi.nlm.nih.gov/16433010","citation_count":216,"is_preprint":false},{"pmid":"18039773","id":"PMC_18039773","title":"Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors.","date":"2007","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18039773","citation_count":199,"is_preprint":false},{"pmid":"9225287","id":"PMC_9225287","title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.","date":"1997","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9225287","citation_count":195,"is_preprint":false},{"pmid":"7557992","id":"PMC_7557992","title":"Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7557992","citation_count":194,"is_preprint":false},{"pmid":"8626761","id":"PMC_8626761","title":"Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626761","citation_count":186,"is_preprint":false},{"pmid":"12650852","id":"PMC_12650852","title":"5-HT2A and 5-HT2C receptors and their atypical regulation properties.","date":"2003","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12650852","citation_count":176,"is_preprint":false},{"pmid":"8876023","id":"PMC_8876023","title":"Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.","date":"1996","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8876023","citation_count":174,"is_preprint":false},{"pmid":"9700207","id":"PMC_9700207","title":"5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease.","date":"1998","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9700207","citation_count":164,"is_preprint":false},{"pmid":"7912626","id":"PMC_7912626","title":"In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.","date":"1994","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7912626","citation_count":157,"is_preprint":false},{"pmid":"10501219","id":"PMC_10501219","title":"Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10501219","citation_count":147,"is_preprint":false},{"pmid":"14623358","id":"PMC_14623358","title":"Serotonin and drug reward: focus on 5-HT2C receptors.","date":"2003","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14623358","citation_count":133,"is_preprint":false},{"pmid":"19304781","id":"PMC_19304781","title":"Loss of the imprinted snoRNA mbii-52 leads to increased 5htr2c pre-RNA editing and altered 5HT2CR-mediated behaviour.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19304781","citation_count":133,"is_preprint":false},{"pmid":"10432493","id":"PMC_10432493","title":"Messenger RNA editing of the human serotonin 5-HT2C receptor.","date":"1999","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10432493","citation_count":124,"is_preprint":false},{"pmid":"14988405","id":"PMC_14988405","title":"The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14988405","citation_count":120,"is_preprint":false},{"pmid":"8867874","id":"PMC_8867874","title":"Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation.","date":"1996","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8867874","citation_count":119,"is_preprint":false},{"pmid":"16785265","id":"PMC_16785265","title":"The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.","date":"2006","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16785265","citation_count":116,"is_preprint":false},{"pmid":"10188965","id":"PMC_10188965","title":"Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10188965","citation_count":115,"is_preprint":false},{"pmid":"20980537","id":"PMC_20980537","title":"Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.","date":"2010","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/20980537","citation_count":115,"is_preprint":false},{"pmid":"12614326","id":"PMC_12614326","title":"Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12614326","citation_count":114,"is_preprint":false},{"pmid":"20089901","id":"PMC_20089901","title":"Enhancement of spatial reversal learning by 5-HT2C receptor antagonism is neuroanatomically specific.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20089901","citation_count":111,"is_preprint":false},{"pmid":"15953671","id":"PMC_15953671","title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.","date":"2005","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/15953671","citation_count":105,"is_preprint":false},{"pmid":"21999473","id":"PMC_21999473","title":"Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.","date":"2011","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21999473","citation_count":104,"is_preprint":false},{"pmid":"17291373","id":"PMC_17291373","title":"Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis.","date":"2007","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17291373","citation_count":98,"is_preprint":false},{"pmid":"17017968","id":"PMC_17017968","title":"Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.","date":"2006","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17017968","citation_count":97,"is_preprint":false},{"pmid":"19109993","id":"PMC_19109993","title":"Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.","date":"2008","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19109993","citation_count":94,"is_preprint":false},{"pmid":"18523738","id":"PMC_18523738","title":"S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.","date":"2008","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18523738","citation_count":94,"is_preprint":false},{"pmid":"12782219","id":"PMC_12782219","title":"Compulsive behavior in the 5-HT2C receptor knockout mouse.","date":"2003","source":"Physiology & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/12782219","citation_count":94,"is_preprint":false},{"pmid":"25770211","id":"PMC_25770211","title":"Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25770211","citation_count":93,"is_preprint":false},{"pmid":"21121776","id":"PMC_21121776","title":"Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.","date":"2010","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/21121776","citation_count":89,"is_preprint":false},{"pmid":"16269190","id":"PMC_16269190","title":"Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.","date":"2005","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16269190","citation_count":88,"is_preprint":false},{"pmid":"8812491","id":"PMC_8812491","title":"The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812491","citation_count":88,"is_preprint":false},{"pmid":"9928241","id":"PMC_9928241","title":"Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928241","citation_count":87,"is_preprint":false},{"pmid":"26739950","id":"PMC_26739950","title":"5-HT2C receptors in psychiatric disorders: A review.","date":"2015","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26739950","citation_count":86,"is_preprint":false},{"pmid":"15087490","id":"PMC_15087490","title":"Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15087490","citation_count":85,"is_preprint":false},{"pmid":"26617215","id":"PMC_26617215","title":"New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.","date":"2015","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26617215","citation_count":84,"is_preprint":false},{"pmid":"9844009","id":"PMC_9844009","title":"Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9844009","citation_count":83,"is_preprint":false},{"pmid":"10220565","id":"PMC_10220565","title":"Novel actions of inverse agonists on 5-HT2C receptor systems.","date":"1999","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10220565","citation_count":82,"is_preprint":false},{"pmid":"7659770","id":"PMC_7659770","title":"The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine.","date":"1995","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7659770","citation_count":79,"is_preprint":false},{"pmid":"15093687","id":"PMC_15093687","title":"Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy.","date":"2004","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15093687","citation_count":75,"is_preprint":false},{"pmid":"17632216","id":"PMC_17632216","title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.","date":"2007","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17632216","citation_count":74,"is_preprint":false},{"pmid":"15935077","id":"PMC_15935077","title":"Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15935077","citation_count":73,"is_preprint":false},{"pmid":"25870913","id":"PMC_25870913","title":"Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.","date":"2015","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25870913","citation_count":72,"is_preprint":false},{"pmid":"10327425","id":"PMC_10327425","title":"Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine.","date":"1999","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10327425","citation_count":72,"is_preprint":false},{"pmid":"12431861","id":"PMC_12431861","title":"Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor.","date":"2002","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12431861","citation_count":72,"is_preprint":false},{"pmid":"16249524","id":"PMC_16249524","title":"Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.","date":"2005","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/16249524","citation_count":71,"is_preprint":false},{"pmid":"24041919","id":"PMC_24041919","title":"From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.","date":"2013","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24041919","citation_count":71,"is_preprint":false},{"pmid":"19142101","id":"PMC_19142101","title":"HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.","date":"2009","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19142101","citation_count":70,"is_preprint":false},{"pmid":"9928237","id":"PMC_9928237","title":"Identification and characterization of RNA editing events within the 5-HT2C receptor.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928237","citation_count":70,"is_preprint":false},{"pmid":"15518545","id":"PMC_15518545","title":"Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15518545","citation_count":70,"is_preprint":false},{"pmid":"12678838","id":"PMC_12678838","title":"5-HT2C receptor agonists as potential drugs for the treatment of obesity.","date":"2003","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12678838","citation_count":69,"is_preprint":false},{"pmid":"20504252","id":"PMC_20504252","title":"Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.","date":"2010","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/20504252","citation_count":68,"is_preprint":false},{"pmid":"10206238","id":"PMC_10206238","title":"Allelic variants of dopamine receptor D4 (DRD4) and serotonin receptor 5HT2c (HTR2c) and temperament factors: replication tests.","date":"1999","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10206238","citation_count":67,"is_preprint":false},{"pmid":"7846211","id":"PMC_7846211","title":"Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety.","date":"1994","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7846211","citation_count":66,"is_preprint":false},{"pmid":"17192951","id":"PMC_17192951","title":"HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers.","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192951","citation_count":64,"is_preprint":false},{"pmid":"19142110","id":"PMC_19142110","title":"Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.","date":"2009","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19142110","citation_count":62,"is_preprint":false},{"pmid":"15048662","id":"PMC_15048662","title":"A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15048662","citation_count":62,"is_preprint":false},{"pmid":"23049953","id":"PMC_23049953","title":"5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23049953","citation_count":61,"is_preprint":false},{"pmid":"20852829","id":"PMC_20852829","title":"Therapeutic potential of 5-HT2C receptor ligands.","date":"2010","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/20852829","citation_count":60,"is_preprint":false},{"pmid":"7583341","id":"PMC_7583341","title":"Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells.","date":"1995","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/7583341","citation_count":60,"is_preprint":false},{"pmid":"8107508","id":"PMC_8107508","title":"Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade?","date":"1994","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/8107508","citation_count":59,"is_preprint":false},{"pmid":"15638778","id":"PMC_15638778","title":"Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs.","date":"2005","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15638778","citation_count":57,"is_preprint":false},{"pmid":"27085605","id":"PMC_27085605","title":"Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27085605","citation_count":57,"is_preprint":false},{"pmid":"16430874","id":"PMC_16430874","title":"Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16430874","citation_count":57,"is_preprint":false},{"pmid":"9928246","id":"PMC_9928246","title":"Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928246","citation_count":56,"is_preprint":false},{"pmid":"20171995","id":"PMC_20171995","title":"Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction.","date":"2010","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/20171995","citation_count":55,"is_preprint":false},{"pmid":"7798914","id":"PMC_7798914","title":"Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus.","date":"1995","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7798914","citation_count":53,"is_preprint":false},{"pmid":"25417553","id":"PMC_25417553","title":"Critical involvement of 5-HT2C receptor function in amphetamine-induced 50-kHz ultrasonic vocalizations in rats.","date":"2014","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25417553","citation_count":52,"is_preprint":false},{"pmid":"8931161","id":"PMC_8931161","title":"Moderate dieting causes 5-HT2C receptor supersensitivity.","date":"1996","source":"Psychological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8931161","citation_count":51,"is_preprint":false},{"pmid":"9282936","id":"PMC_9282936","title":"Activating mutations of the serotonin 5-HT2C receptor.","date":"1997","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9282936","citation_count":51,"is_preprint":false},{"pmid":"36373384","id":"PMC_36373384","title":"Depressive patient-derived GABA interneurons reveal abnormal neural activity associated with HTR2C.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36373384","citation_count":49,"is_preprint":false},{"pmid":"16503763","id":"PMC_16503763","title":"The potential use of selective 5-HT2C agonists in treating obesity.","date":"2006","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/16503763","citation_count":49,"is_preprint":false},{"pmid":"14996615","id":"PMC_14996615","title":"The 5-HT2C receptor as a target for mood disorders.","date":"2004","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/14996615","citation_count":47,"is_preprint":false},{"pmid":"20680028","id":"PMC_20680028","title":"Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.","date":"2010","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/20680028","citation_count":47,"is_preprint":false},{"pmid":"19434072","id":"PMC_19434072","title":"Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19434072","citation_count":46,"is_preprint":false},{"pmid":"17073648","id":"PMC_17073648","title":"Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?","date":"2006","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17073648","citation_count":46,"is_preprint":false},{"pmid":"19439249","id":"PMC_19439249","title":"Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.","date":"2009","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19439249","citation_count":45,"is_preprint":false},{"pmid":"31288724","id":"PMC_31288724","title":"Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development.","date":"2019","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31288724","citation_count":44,"is_preprint":false},{"pmid":"31778691","id":"PMC_31778691","title":"Anxiety during alcohol withdrawal involves 5-HT2C receptors and M-channels in the lateral habenula.","date":"2019","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31778691","citation_count":44,"is_preprint":false},{"pmid":"10432492","id":"PMC_10432492","title":"Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD).","date":"1999","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10432492","citation_count":44,"is_preprint":false},{"pmid":"8748393","id":"PMC_8748393","title":"5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.","date":"1995","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8748393","citation_count":43,"is_preprint":false},{"pmid":"18600561","id":"PMC_18600561","title":"Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.","date":"2008","source":"Current opinion in drug discovery & development","url":"https://pubmed.ncbi.nlm.nih.gov/18600561","citation_count":42,"is_preprint":false},{"pmid":"9972850","id":"PMC_9972850","title":"5-HT2A and 5-HT2C/5-HT1B receptors are differentially involved in alcohol preference and consummatory behavior in cAA rats.","date":"1999","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/9972850","citation_count":42,"is_preprint":false},{"pmid":"17016522","id":"PMC_17016522","title":"The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.","date":"2006","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/17016522","citation_count":42,"is_preprint":false},{"pmid":"17376412","id":"PMC_17376412","title":"5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17376412","citation_count":40,"is_preprint":false},{"pmid":"30120415","id":"PMC_30120415","title":"5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy.","date":"2018","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/30120415","citation_count":38,"is_preprint":false},{"pmid":"21967853","id":"PMC_21967853","title":"Cortisol responses to emotional stress in men: association with a functional polymorphism in the 5HTR2C gene.","date":"2011","source":"Biological psychology","url":"https://pubmed.ncbi.nlm.nih.gov/21967853","citation_count":38,"is_preprint":false},{"pmid":"17702092","id":"PMC_17702092","title":"HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis.","date":"2007","source":"Human psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17702092","citation_count":38,"is_preprint":false},{"pmid":"14722258","id":"PMC_14722258","title":"RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA.","date":"2004","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14722258","citation_count":38,"is_preprint":false},{"pmid":"22436698","id":"PMC_22436698","title":"Serotonin 5-HT2C receptor-mediated inhibition of the M-current in hypothalamic POMC neurons.","date":"2012","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22436698","citation_count":37,"is_preprint":false},{"pmid":"12815163","id":"PMC_12815163","title":"Positive allosteric modulator of the human 5-HT2C receptor.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12815163","citation_count":36,"is_preprint":false},{"pmid":"24618688","id":"PMC_24618688","title":"Variation within the serotonin (5-HT) 5-HT₂C receptor system aligns with vulnerability to cocaine cue reactivity.","date":"2014","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24618688","citation_count":36,"is_preprint":false},{"pmid":"17449447","id":"PMC_17449447","title":"Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment.","date":"2007","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/17449447","citation_count":35,"is_preprint":false},{"pmid":"18715570","id":"PMC_18715570","title":"Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls.","date":"2008","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/18715570","citation_count":35,"is_preprint":false},{"pmid":"25732952","id":"PMC_25732952","title":"Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders.","date":"2015","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25732952","citation_count":35,"is_preprint":false},{"pmid":"24935789","id":"PMC_24935789","title":"Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats.","date":"2014","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24935789","citation_count":35,"is_preprint":false},{"pmid":"18176661","id":"PMC_18176661","title":"5-HT2C receptor agonists as an innovative approach for psychiatric disorders.","date":"2007","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/18176661","citation_count":34,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50692,"output_tokens":8555,"usd":0.140201,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18343,"output_tokens":5997,"usd":0.12082,"stage2_stop_reason":"end_turn"},"total_usd":0.261021,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"5-HT2C receptor-deficient (knockout) mice are overweight due to abnormal control of feeding behaviour, establishing a role for this receptor in serotonergic control of appetite; mutant animals also exhibit spontaneous death from seizures, implicating 5-HT2C receptors in tonic inhibition of neuronal network excitability.\",\n      \"method\": \"Targeted gene knockout mice with phenotypic readouts (body weight, food intake, seizure susceptibility)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple specific phenotypic readouts (obesity, epilepsy), widely replicated across subsequent studies\",\n      \"pmids\": [\"7700379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A Cys23Ser substitution in the first hydrophobic region of the human 5-HT2C receptor (HTR2C on Xq24) was identified; when expressed in Xenopus oocytes, concentration-response curves to 5-HT were not significantly different between the two forms, indicating no functional difference under baseline conditions.\",\n      \"method\": \"SSCP analysis, linkage analysis, heterologous expression in Xenopus oocytes with electrophysiological recording\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional assay in Xenopus oocytes with electrophysiology; single lab, negative result reported\",\n      \"pmids\": [\"7557992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Activation of 5-HT2C receptors stimulates APP ectodomain (APPs) secretion via a mechanism requiring both PKC and phospholipase A2 (PLA2), as demonstrated in 3T3 cells stably overexpressing 5-HT2cR; this is distinct from 5-HT2A receptor coupling, which requires PLA2 but not PKC.\",\n      \"method\": \"Stable cell line overexpression, pharmacological inhibitors of PKC and PLA2, APPs secretion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with pharmacological dissection; single lab, two orthogonal inhibitor approaches\",\n      \"pmids\": [\"8626761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Activation of 5-HT2C receptor in choroid plexus triggers cyclic GMP (cGMP) formation in a calcium-, phospholipase A2-, and lipoxygenase-dependent manner, in addition to phosphoinositide turnover.\",\n      \"method\": \"Porcine choroid plexus tissue slices, pharmacological antagonists, cGMP assay, pertussis toxin pretreatment, PLA2 and lipoxygenase inhibitors\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo tissue preparation with pharmacological dissection; single lab, multiple inhibitor conditions\",\n      \"pmids\": [\"7798914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human 5-HT2C receptor gene (HTR2C) contains six exons and five introns spanning at least 230 kb; an alternatively spliced isoform with a 95-nt deletion in the region coding for the second intracellular loop produces a truncated 248-aa protein. Transcription initiates at multiple sites with no classical TATA box.\",\n      \"method\": \"Genomic cloning, cDNA isolation, sequencing, RT-PCR, luciferase reporter assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization; single lab, multiple orthogonal molecular methods\",\n      \"pmids\": [\"8812491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Fluoxetine and other SSRIs (norfluoxetine, citalopram) act as antagonists at the 5-HT2C receptor, inhibiting 5-HT-stimulated phosphoinositide hydrolysis without inverse agonist activity, as demonstrated in choroid plexus and clonal cell lines expressing the cloned rat 5-HT2C receptor.\",\n      \"method\": \"Radioligand binding ([3H]mesulergine), phosphoinositide (PI) hydrolysis assay, cloned receptor cell lines and rat choroid plexus\",\n      \"journal\": \"Psychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional PI hydrolysis assay combined with radioligand binding; single lab, two orthogonal methods\",\n      \"pmids\": [\"8876023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RNA editing of the 5-HT2C receptor at four major adenosine-to-inosine positions (A, B, C, D) in the second intracellular loop alters receptor isoforms' ability to interact with the phospholipase C signaling cascade; editing is mediated by at least two members of the ADAR family and requires an extensive RNA duplex structure formed by exonic and intronic sequences of 5-HT2C pre-mRNA.\",\n      \"method\": \"In vitro transcription, ADAR family enzyme assays, transfected cell line functional assays (phospholipase C coupling), structural analysis of RNA duplex\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro editing assays with functional validation; replicated across multiple subsequent studies\",\n      \"pmids\": [\"9928237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Site-directed mutagenesis of serine 312 to phenylalanine (S312F) or lysine (S312K) in the 5-HT2C receptor creates constitutively active receptors that spontaneously couple to G proteins and stimulate phosphatidylinositol hydrolysis in the absence of agonist; mianserin and mesulergine act as inverse agonists on the S312K mutant receptor.\",\n      \"method\": \"Site-directed mutagenesis, COS-7 cell expression, [3H]mesulergine and [3H]5-HT radioligand binding, PI hydrolysis assay, GppNHp treatment\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution via site-directed mutagenesis with functional validation of constitutive activity and inverse agonism; rigorous single study with multiple assays\",\n      \"pmids\": [\"9282936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RNA editing of the 5-HT2C receptor decreases receptor basal (constitutive) activity, agonist affinity, and agonist potency for inositol phosphate production. The non-edited isoform (INI) shows fourfold greater basal IP production than the fully edited isoform (VGV); 5-HT competes for two binding sites on INI but only one site on VGV.\",\n      \"method\": \"COS-7 cell transient expression, inositol phosphate assay, radioligand binding ([3H]mesulergine, [3H]5-HT), dose-response analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro functional reconstitution with multiple receptor isoforms, multiple assay endpoints; replicated by subsequent studies\",\n      \"pmids\": [\"10501219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RNA editing of the human 5-HT2C receptor at five sites (including a novel 5th site) reduces agonist binding affinity and functional potency in proportion to agonist intrinsic activity; full agonists are most affected and antagonists are unaffected, suggesting editing alters coupling energetics within the ternary complex.\",\n      \"method\": \"Analysis of human brain/hypothalamic RNA, cloning of isoforms, radioligand binding and functional assays in recombinant receptor systems\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct functional characterization of multiple human receptor isoforms with binding and functional assays; replicated finding\",\n      \"pmids\": [\"10432493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Prolonged treatment (24 h) with inverse agonists at human 5-HT2C receptors selectively enhances 5-HT2C-mediated inositol phosphate (IP) accumulation but not arachidonic acid (AA) release; this enhanced responsiveness is not due to receptor up-regulation but may involve changes in expression of Gαq/11 and possibly Gα12/Gα13.\",\n      \"method\": \"CHO cells stably expressing human 5-HT2C receptor, IP accumulation assay, AA release assay, pharmacological dissection with neutral antagonists and agonists\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable cell line functional assays with multiple ligand conditions; single lab, two orthogonal signaling readouts\",\n      \"pmids\": [\"10220565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LSD signals differently from serotonin (5-HT) at the 5-HT2C receptor; specifically, RNA editing of the 5-HT2C receptor dramatically alters the ability of LSD to stimulate phosphatidylinositol signaling, demonstrating agonist-directed trafficking at this receptor.\",\n      \"method\": \"Cell-based phosphatidylinositol signaling assay with edited and non-edited receptor isoforms, comparison of LSD vs. 5-HT efficacy\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based assay with multiple isoforms; single lab, limited methodological detail in abstract\",\n      \"pmids\": [\"10432492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"5-HT2C receptors in the hippocampal formation are required for normal long-term potentiation specifically at medial perforant path-dentate gyrus synapses; 5-HT2C receptor null mutant mice show selective LTP impairment at this synapse accompanied by abnormal Morris water maze performance and reduced novelty aversion.\",\n      \"method\": \"5-HT2C receptor knockout mice, electrophysiological LTP recording at four hippocampal pathways, Morris water maze behavioral testing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with targeted electrophysiological readout at specific synapse plus behavioral validation; multiple orthogonal methods\",\n      \"pmids\": [\"9844009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"5-HT2C receptor protein is expressed on neuronal cell bodies throughout the CNS, including hippocampus, amygdala, thalamus, caudate-putamen, cortex, and dorsal raphé nuclei, consistent with postsynaptic localization to serotonergic neurons and possible autoreceptor function in raphé.\",\n      \"method\": \"Immunohistochemistry with polyclonal antibodies against rat 5-HT2C receptor protein, Western blot, immunofluorescence in transfected HEK293 cells, peptide competition controls\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunohistochemistry with antibody validation (Western blot, peptide competition, transfected cell controls); single lab\",\n      \"pmids\": [\"10665825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The 5-HT2C receptor C-terminus (PDZ ligand SXV) interacts with a specific set of PDZ proteins distinct from those binding the 5-HT2A receptor: 5-HT2C binds the Veli-3·CASK·Mint1 ternary complex, SAP102, PSD-95, and MPP-3; residues at the -1 position and upstream of the PDZ ligand determine partner specificity. These interactions occur in intracellular compartments in living cells.\",\n      \"method\": \"Affinity chromatography with immobilized synthetic PDZ ligand peptides, mass spectrometry, co-immunoprecipitation, immunofluorescence, electron microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — proteomic affinity chromatography plus MS identification, confirmed by co-IP and cellular imaging; multiple orthogonal methods in single study\",\n      \"pmids\": [\"14988405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RNA editing of the human 5-HT2C receptor modulates splice site selection; editing at multiple sites in a stable stem-loop encompassing the normal and alternative 5' splice sites of intron 5 profoundly alters relative splicing at normal versus alternative upstream splice sites, linking A-to-I editing to control of pre-mRNA splicing.\",\n      \"method\": \"In vitro editing, cell culture base-substitution experiments, human brain splice variant analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro editing reconstitution combined with cell culture mutational analysis and human brain validation; multiple orthogonal methods\",\n      \"pmids\": [\"15087490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RNA editing at the non-edited (INI) 5-HT2C receptor isoform activates phospholipase D via the G13 heterotrimer G-protein, requiring transactivation of the small G-protein RhoA; the fully edited VGV isoform does not activate RhoA or phospholipase D, demonstrating that editing regulates signaling pathway selection including pathways linked to actin cytoskeletal organization.\",\n      \"method\": \"Transfected cell lines expressing INI vs. VGV isoforms, phospholipase D activity assay, RhoA activation assay, pharmacological G-protein inhibitors\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro functional reconstitution with isoform comparison, multiple signaling pathway assays, and mechanistic dissection; single rigorous study\",\n      \"pmids\": [\"14722258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"5-HT2C receptors exist as constitutive homodimers on the plasma membrane of living cells, demonstrated by immunoprecipitation/Western blot showing monomer and dimer bands, BRET (Renilla luciferase/YFP), and confocal FRET (CFP/YFP donor-acceptor pairs) on the plasma membrane; BRET levels were not altered by serotonin pretreatment, indicating constitutive (agonist-independent) dimerization.\",\n      \"method\": \"Immunoprecipitation, Western blot, BRET in HEK293 cells, confocal FRET by acceptor photobleaching\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — three independent biophysical methods (IP/WB, BRET, FRET) all demonstrating homodimerization in living cells; rigorous single study\",\n      \"pmids\": [\"15518545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Interferon-alpha (IFN-α) rapidly alters ADAR1 expression and the pattern of 5-HT2C receptor mRNA editing in human glioblastoma cells, leading to dominant expression of the 5-HT2C-VSI isoform predicted to have reduced G-protein coupling functions.\",\n      \"method\": \"Human glioblastoma cell line treatment with IFN-α, RT-PCR analysis of editing patterns, ADAR1 expression analysis\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based experiment with direct measurement of editing changes; single lab, limited mechanistic follow-up in abstract\",\n      \"pmids\": [\"15093687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"5-HT2C receptor couples to ERK1/2 via a pathway requiring phospholipase D, protein kinase C, and the Raf/MEK/ERK module, but independent of receptor and non-receptor tyrosine kinases, PLC, PI3K, and endocytosis; agonist-directed trafficking was observed whereby DOI and quipazine showed reversal of efficacy between PI/Ca2+ pathways and ERK1/2 phosphorylation.\",\n      \"method\": \"CHO cells stably expressing non-edited 5-HT2C receptor, ERK1/2 phosphorylation assay, pharmacological inhibitors of multiple signaling intermediates\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic pharmacological dissection of signaling pathway with multiple inhibitors and multiple readouts in a defined cell system; single rigorous study\",\n      \"pmids\": [\"15935077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PNU-69176E acts as a positive allosteric modulator (PAM) of the human 5-HT2C receptor; at low micromolar concentrations it markedly enhances [3H]5-HT binding (>300%) by increasing agonist affinity without affecting antagonist binding ([3H]mesulergine), and renders receptors constitutively active (GTPγS binding, IP3 release, IP accumulation). This selectivity is for 5-HT2C over 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, D2L, and D3 receptors.\",\n      \"method\": \"Radioligand binding, GTPγS binding, IP3 measurement, IP accumulation assay across multiple cell lines and receptor types; structure-activity relationship of alkyl chain length\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with multiple functional endpoints, receptor selectivity panel, and SAR; single rigorous study\",\n      \"pmids\": [\"12815163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"5-HT2C receptor agonism produces hypophagia downstream via activation of melanocortin 4 receptors (MC4R); 5-HT2CRs are coexpressed with POMC neurons in the arcuate nucleus, and mice lacking MC4R are not responsive to 5-HT2CR agonist-induced hypophagia, establishing that melanocortins acting on MC4R are a requisite downstream pathway.\",\n      \"method\": \"Coexpression studies (5-HT2CR/POMC), chronic BVT.X infusion in obese mice measuring Pomc mRNA and body weight, genetic epistasis using MC4R knockout mice\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (MC4R KO) combined with neuroanatomical coexpression and Pomc mRNA measurement; multiple orthogonal approaches\",\n      \"pmids\": [\"18039773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"5-HT2C and 5-HT2A receptors exhibit agonist-directed trafficking of receptor stimulus: relative efficacies of agonists differ depending on whether phospholipase C-mediated IP accumulation or PLA2-mediated arachidonic acid release is measured, demonstrating that different agonists selectively activate subsets of multiple signaling pathways coupled to a single receptor.\",\n      \"method\": \"Cell-based assays measuring IP accumulation and arachidonic acid release with multiple agonists; relative efficacy referenced to 5-HT\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based assays with multiple agonists and two parallel signaling readouts; single lab\",\n      \"pmids\": [\"9928246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Loss of the imprinted snoRNA mbii-52 (h/mbii-52) in a mouse model of Prader-Willi syndrome leads to increased A-to-I editing of the 5-HT2C receptor (5htr2c) pre-RNA, establishing that mbii-52 negatively regulates 5htr2c editing in vivo; increased editing is associated with alterations in 5-HT2CR-related behaviours (impulsive responding, locomotor activity, food reactivity) confirmed by pharmacological challenge.\",\n      \"method\": \"PWS-IC+/- mouse model, quantitative editing analysis, behavioral testing with pharmacological (5-HT2CR drug challenge) confirmation of mechanism\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function model with direct measurement of editing changes, multiple behavioral readouts, and pharmacological confirmation of 5-HT2CR specificity\",\n      \"pmids\": [\"19304781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"5-HT2C receptor antagonism within the orbitofrontal cortex (OFC), but not the medial prefrontal cortex or nucleus accumbens, improves spatial reversal learning by reducing perseverative errors, establishing a neuroanatomically specific role for OFC 5-HT2C receptors in cognitive flexibility.\",\n      \"method\": \"Site-specific intracerebral microinfusion of selective 5-HT2C antagonist SB 242084 into OFC, mPFC, or NAc; spatial reversal learning behavioral paradigm\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted intracerebral infusion with specific behavioral readout; single lab, dose-response within OFC\",\n      \"pmids\": [\"20089901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"After spinal cord injury, 5-HT2B and 5-HT2C receptors on motoneurons become constitutively active and facilitate persistent calcium currents (Ca PICs) and long-lasting reflexes (muscle spasms); inverse agonists blocking constitutive 5-HT2C/2B activity reduce spasms, while neutral antagonists (which do not block constitutive activity) have no effect alone.\",\n      \"method\": \"Chronic spinal rat in vitro preparation, ventral root recording of long-lasting reflexes, intracellular recording of Ca PICs, selective agonists/antagonists/inverse agonists, immunolabeling of 5-HT2B/2C on motoneurons\",\n      \"journal\": \"Journal of neurophysiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological dissection distinguishing agonist, neutral antagonist, and inverse agonist effects; confirmed by immunolabeling; clean constitutive activity demonstration in vivo\",\n      \"pmids\": [\"20980537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"5-HT2C receptor activation in hypothalamic POMC neurons inhibits the M-current (KCNQ channel-mediated) by 34–42%, increasing neuronal excitability; the selective 5-HT2C antagonist RS-102221 abrogates this effect, establishing 5-HT2C-mediated inhibition of M-current as a mechanism for serotonin-induced POMC activation and reduced food intake.\",\n      \"method\": \"Visualized-patch clamp recording in eGFP-POMC transgenic mouse hypothalamic neurons, selective pharmacological agonists/antagonists (DOI, mCPP, RS-102221), KCNQ blocker XE-991\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct electrophysiology in identified neurons with selective pharmacological validation; multiple agonists and antagonist confirmation\",\n      \"pmids\": [\"22436698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Melatonin MT2 and 5-HT2C receptors form functional heteromers both in transfected cells and in human cortex and hippocampus; MT2/5-HT2C heteromers amplify 5-HT-mediated Gq/PLC response and enable melatonin-induced unidirectional transactivation of the 5-HT2C protomer; the antidepressant agomelatine shows biased signaling at these heteromers.\",\n      \"method\": \"Co-immunoprecipitation, bioluminescence resonance energy transfer (BRET), pharmacological assays in transfected cells and human brain tissue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — three independent methods (co-IP, BRET, pharmacology) demonstrating heteromer formation with functional consequences; validated in human brain tissue\",\n      \"pmids\": [\"25770211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SSRIs impair motor function through 5-HT2C receptors in the substantia nigra pars reticulata (SNr), which inhibit dopaminergic neurons in the substantia nigra pars compacta (SNc); SSRI-induced SNr hyperactivity and SNc hypoactivity are reversed by systemic or SNr-localized 5-HT2C receptor antagonism; optogenetic inhibition of SNc neurons mimics SSRI motor deficits and 5-HT2C antagonism or optogenetic SNc activation reverses them.\",\n      \"method\": \"Mouse model with systemic SSRIs, localized SNr 5-HT2C receptor antagonism, optogenetic activation/inhibition of SNc dopaminergic neurons, motor function behavioral assays\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological circuit dissection combined with optogenetics and site-specific antagonism; multiple orthogonal methods establishing SNr 5-HT2C → SNc DA pathway\",\n      \"pmids\": [\"30120415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"5-HT2C receptor null mutant mice show more wakefulness, abnormalities in REM sleep expression, and enhanced response to sleep deprivation compared to wild-type mice, establishing a role for 5-HT2C receptors in sleep expression and sleep homeostasis.\",\n      \"method\": \"5-HT2C receptor knockout mice, polysomnographic sleep recording, sleep deprivation protocol\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with quantitative sleep recording; multiple sleep stage phenotypes\",\n      \"pmids\": [\"12431861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"5-HT2C receptor promoter polymorphisms (-759C/T and -697G/C) alter promoter activity in SH-SY5Y neuroblastoma cells; the -759T and -697C alleles reduce promoter activity, and the haplotype associated with resistance to antipsychotic-induced weight gain shows reduced activity compared to the most common haplotype.\",\n      \"method\": \"Luciferase reporter constructs with four promoter haplotypes transfected into SH-SY5Y cells, in presence or absence of constitutively active 5-HT2C receptor\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional promoter assay with multiple haplotypes; single lab\",\n      \"pmids\": [\"17376412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the lateral habenula (LHb), 5-HT2C receptor levels and 5-HIAA/5-HT ratio are increased in alcohol-withdrawn rats; intra-LHb 5-HT2C receptor antagonism (SB242084) alleviates anxiety-like behaviors and reduces elevated c-Fos expression, and increases KCNQ2/3 membrane protein expression in LHb, establishing that enhanced LHb 5-HT2C receptor signaling interacts with M-channels to trigger withdrawal anxiety.\",\n      \"method\": \"Intra-LHb microinfusion of SB242084 or WAY161503, elevated plus-maze, open-field, marble-burying tests, c-Fos immunohistochemistry, Western blot of KCNQ2/3 and 5-HT2C protein\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-specific pharmacological manipulation with multiple behavioral and molecular readouts; single lab\",\n      \"pmids\": [\"31778691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In iPSC-derived GABAergic interneurons from patients with major depressive disorder with suicide behavior (sMDD), 5-HT2C receptor expression is decreased and neuronal activity is abnormal (increased firing, weakened calcium signaling); pharmacological agonism or genetic restoration of 5-HT2C receptor rescues neuronal activity deficits, establishing 5-HT2C as a mechanistic determinant of interneuron dysfunction in sMDD.\",\n      \"method\": \"iPSC-derived GABAergic interneurons and ventral forebrain organoids from sMDD patients, transcriptomic sequencing, calcium imaging, electrophysiology, pharmacological and genetic 5-HT2C receptor manipulation\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human iPSC loss-of-function model with multiple functional readouts and rescue experiments; single lab\",\n      \"pmids\": [\"36373384\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HTR2C (5-HT2C receptor) is a constitutively active, class A GPCR that couples primarily to Gq/11 to activate phospholipase C (IP production), and additionally to G13/RhoA to activate phospholipase D, as well as to PLA2-cGMP and ERK1/2 pathways via PKC and Raf/MEK; its signaling is profoundly regulated by A-to-I RNA editing of up to five sites in the second intracellular loop (controlled by ADAR enzymes and negatively regulated by snoRNA mbii-52), which reduces constitutive activity, agonist affinity and G-protein coupling efficiency, and also modulates splice site selection; the receptor forms constitutive homodimers and functional heteromers with melatonin MT2 receptors on the plasma membrane; it interacts via its C-terminal PDZ ligand with scaffolding proteins including PSD-95, SAP102, and the Veli-3·CASK·Mint1 complex; in the hypothalamus it is co-expressed with POMC neurons where it suppresses the M-current to increase neuronal excitability and drives hypophagia downstream through melanocortin 4 receptors; in the substantia nigra pars reticulata 5-HT2C receptor activation inhibits SNc dopaminergic neurons; and in motoneurons after spinal cord injury the receptor becomes constitutively active to facilitate persistent calcium currents and muscle spasms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HTR2C encodes the serotonin 5-HT2C receptor, a constitutively active class A GPCR that governs serotonergic control of appetite, neuronal network excitability, sleep, and cognitive flexibility, as established genetically by knockout mice that become obese and die from spontaneous seizures [#0, #29]. The receptor couples through multiple signaling routes: it activates phospholipase C-driven inositol phosphate production [#8], engages a G13/RhoA-dependent phospholipase D pathway [#16], and drives ERK1/2 phosphorylation via PLD, PKC, and the Raf/MEK module [#19], with agonists showing biased efficacy across these PLC, PLA2, and ERK outputs (agonist-directed trafficking) [#11, #22]. Receptor activity is intrinsically constitutive, demonstrated by activating mutations at serine 312 that confer agonist-independent G-protein coupling and reveal inverse agonism by ligands such as mianserin [#7]. A defining regulatory feature is A-to-I RNA editing at up to five sites in the second intracellular loop, mediated by ADAR enzymes acting on an exon-intron RNA duplex; editing reduces basal activity, agonist affinity, and coupling efficiency (non-edited INI vs. fully edited VGV isoforms) and selects which downstream pathways the receptor engages, and the same stem-loop links editing to alternative splice-site choice [#6, #8, #9, #15, #16]. This editing is constrained in vivo by the imprinted snoRNA mbii-52 and is modulated by interferon-alpha via ADAR1 [#23, #18]. The receptor's C-terminal PDZ ligand recruits scaffolding proteins including PSD-95, SAP102, MPP-3, and the Veli-3·CASK·Mint1 complex [#14], and it forms constitutive homodimers and functional heteromers with the melatonin MT2 receptor that amplify Gq/PLC signaling and permit transactivation [#17, #27]. In hypothalamic POMC neurons it inhibits the KCNQ-mediated M-current to raise excitability and produces hypophagia that requires downstream melanocortin MC4 receptors [#26, #21]. Circuit-level studies place 5-HT2C in the substantia nigra pars reticulata, where activation inhibits SNc dopaminergic neurons and underlies SSRI-induced motor deficits [#28], and in spinal motoneurons, where injury renders the receptor constitutively active to drive persistent calcium currents and muscle spasms reversible by inverse agonists [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the physiological role of 5-HT2C addressed whether this receptor controls organismal feeding and network excitability rather than acting as a redundant serotonin receptor.\",\n      \"evidence\": \"Targeted knockout mice scored for body weight, food intake, and seizure susceptibility\",\n      \"pmids\": [\"7700379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the cell types or circuits mediating appetite vs. seizure phenotypes\", \"Mechanism linking receptor loss to network hyperexcitability unresolved at the molecular level\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Early functional and structural characterization defined the receptor's signaling outputs beyond simple phosphoinositide turnover and its gene architecture.\",\n      \"evidence\": \"Choroid plexus tissue assays for cGMP/PI turnover, 3T3 cell APPs secretion with PKC/PLA2 inhibitors, and genomic cloning of the six-exon gene with an alternatively spliced isoform\",\n      \"pmids\": [\"7798914\", \"8626761\", \"8812491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The physiological relevance of cGMP and APPs outputs in neurons was not established\", \"Functional consequence of the truncated splice isoform not determined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that point mutations at serine 312 produce agonist-independent coupling answered whether 5-HT2C possesses intrinsic constitutive activity and whether ligands can act as inverse agonists.\",\n      \"evidence\": \"Site-directed mutagenesis (S312F/S312K) in COS-7 cells with radioligand binding and PI hydrolysis assays\",\n      \"pmids\": [\"9282936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether wild-type receptor shows comparable constitutive activity in native tissue was not addressed here\", \"Structural basis of the conformational switch not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery of A-to-I RNA editing in the second intracellular loop answered how a single gene generates functionally distinct receptor isoforms.\",\n      \"evidence\": \"In vitro ADAR editing assays with RNA duplex structural analysis and PLC coupling assays of edited isoforms\",\n      \"pmids\": [\"9928237\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue- and disease-specific editing patterns not yet quantified\", \"Relative contribution of individual ADAR family members not separated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Documenting differential agonist efficacy across PLC versus PLA2 readouts established that a single receptor activates distinct signaling subsets (agonist-directed trafficking).\",\n      \"evidence\": \"Cell-based IP accumulation and arachidonic acid release assays with multiple agonists\",\n      \"pmids\": [\"9928246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of biased coupling (distinct receptor conformations vs. G-protein availability) not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Quantitative isoform comparison established that editing tunes receptor pharmacology, reducing basal activity, agonist affinity, and coupling in proportion to agonist efficacy.\",\n      \"evidence\": \"COS-7 expression of INI vs. VGV and multi-site human isoforms with IP and radioligand binding assays, including LSD versus 5-HT trafficking\",\n      \"pmids\": [\"10501219\", \"10432493\", \"10432492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo editing ratios across brain regions and their behavioral impact not yet linked\", \"Energetic model of ternary-complex alteration inferred rather than structurally demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Chronic inverse agonist studies probed how constitutive activity adapts, showing pathway-selective sensitization of IP but not arachidonic acid signaling.\",\n      \"evidence\": \"CHO cells stably expressing human 5-HT2C with IP and AA release assays under chronic ligand treatment\",\n      \"pmids\": [\"10220565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct evidence for Galpha subunit expression changes was inferential\", \"Relevance to chronic drug treatment in vivo not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Sleep phenotyping of knockout mice extended the receptor's physiological role to sleep expression and homeostasis.\",\n      \"evidence\": \"Polysomnographic recording in 5-HT2C null mice with sleep deprivation challenge\",\n      \"pmids\": [\"12431861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circuit and signaling mechanisms underlying altered wakefulness not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of a selective positive allosteric modulator answered whether 5-HT2C affinity and constitutive activity could be pharmacologically enhanced from an allosteric site.\",\n      \"evidence\": \"Radioligand binding, GTPgammaS, IP3, and IP assays across a receptor selectivity panel with SAR analysis of PNU-69176E\",\n      \"pmids\": [\"12815163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allosteric binding site location not mapped\", \"In vivo efficacy of the PAM not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defining the C-terminal PDZ interactome and homodimerization established how the receptor is scaffolded and organized at the membrane.\",\n      \"evidence\": \"Affinity chromatography/MS, co-IP, and imaging for PDZ partners; IP/WB, BRET, and FRET for constitutive homodimers\",\n      \"pmids\": [\"14988405\", \"15518545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of each scaffold interaction for signaling/trafficking not dissected\", \"Whether dimerization affects coupling efficiency not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mechanistic studies connected editing to both pathway selection and splicing, showing editing controls G13/RhoA/PLD coupling and intron 5 splice-site choice.\",\n      \"evidence\": \"Isoform-specific PLD and RhoA assays with G-protein inhibitors; in vitro editing plus base-substitution splicing analysis with human brain validation; IFN-alpha modulation of ADAR1/editing in glioblastoma cells\",\n      \"pmids\": [\"14722258\", \"15087490\", \"15093687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo coupling between editing-driven splicing and receptor function not quantified\", \"Physiological triggers of IFN-alpha-mediated editing changes in brain unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Pathway dissection of ERK1/2 activation defined a PLD/PKC/Raf-MEK route independent of tyrosine kinases, PLC, and endocytosis, reinforcing biased signaling.\",\n      \"evidence\": \"ERK1/2 phosphorylation assays in CHO cells with a panel of pathway inhibitors and divergent agonists\",\n      \"pmids\": [\"15935077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional/cellular consequences of ERK activation not addressed\", \"Endogenous neuronal validation absent\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Genetic epistasis established the downstream circuit for hypophagia, placing MC4R-expressing melanocortin signaling as a requisite effector of 5-HT2C anorectic action.\",\n      \"evidence\": \"POMC coexpression studies, chronic agonist infusion in obese mice, and MC4R knockout epistasis; plus promoter haplotype reporter assays linking polymorphisms to weight-gain susceptibility\",\n      \"pmids\": [\"18039773\", \"17376412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter polymorphism findings (Medium) await in vivo validation\", \"Exact synaptic relationship between 5-HT2C+ neurons and POMC/MC4R circuit not fully mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying snoRNA mbii-52 as a negative regulator of editing established an in vivo control point linking the Prader-Willi locus to 5-HT2C function.\",\n      \"evidence\": \"PWS-IC+/- mouse model with quantitative editing analysis and pharmacologically confirmed behavioral readouts\",\n      \"pmids\": [\"19304781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which mbii-52 suppresses editing not defined\", \"Contribution to the full Prader-Willi phenotype not isolated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Region-specific pharmacological manipulation localized cognitive-flexibility and spinal motor roles, distinguishing where the receptor exerts behavioral and constitutive-activity effects.\",\n      \"evidence\": \"Intra-OFC antagonist microinfusion in a reversal-learning task; chronic spinal rat preparation distinguishing agonist, neutral antagonist, and inverse agonist effects on Ca PICs and reflexes\",\n      \"pmids\": [\"20089901\", \"20980537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular signaling underlying OFC behavioral effect not defined\", \"How spinal injury triggers acquired constitutive activity is unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Direct electrophysiology in identified POMC neurons established M-current (KCNQ) inhibition as the ionic mechanism by which 5-HT2C raises excitability to suppress feeding.\",\n      \"evidence\": \"Visualized patch-clamp in eGFP-POMC neurons with selective agonists/antagonists and KCNQ blockade\",\n      \"pmids\": [\"22436698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates linking receptor to KCNQ channel closure not delineated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration of MT2/5-HT2C heteromers in human brain established a cross-receptor signaling module relevant to antidepressant action.\",\n      \"evidence\": \"Co-IP, BRET, and pharmacology in transfected cells and human cortex/hippocampus, including agomelatine bias\",\n      \"pmids\": [\"25770211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological and behavioral significance of the heteromer in vivo not established\", \"Stoichiometry and structural arrangement unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Circuit dissection placed SNr 5-HT2C upstream of SNc dopaminergic inhibition, explaining SSRI-induced motor deficits.\",\n      \"evidence\": \"SSRI treatment with site-specific SNr antagonism and optogenetic manipulation of SNc neurons in mice\",\n      \"pmids\": [\"30120415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous signaling of SNr 5-HT2C not resolved\", \"Editing/isoform contribution to this circuit not examined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Lateral habenula studies extended the receptor-M-channel relationship to a withdrawal-anxiety circuit.\",\n      \"evidence\": \"Intra-LHb antagonist/agonist microinfusion with behavioral tests, c-Fos, and KCNQ2/3 Western blot in alcohol-withdrawn rats\",\n      \"pmids\": [\"31778691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab pharmacological study without genetic confirmation\", \"Direct electrophysiological link to M-current in LHb not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Human iPSC modeling connected reduced 5-HT2C expression to GABAergic interneuron dysfunction in suicidal depression, with rescue establishing causality.\",\n      \"evidence\": \"iPSC-derived interneurons and organoids from sMDD patients with calcium imaging, electrophysiology, and pharmacological/genetic 5-HT2C restoration\",\n      \"pmids\": [\"36373384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab human model not replicated\", \"Mechanism linking receptor loss to altered firing/calcium signaling not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RNA-editing-defined isoforms, biased signaling, dimerization/heteromerization, and scaffolding are integrated within specific neuronal circuits to produce distinct behavioral outputs remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of edited vs. unedited receptor coupling states\", \"Causal in vivo role of MT2 heteromers and PDZ scaffolds not established\", \"Mechanism of acquired constitutive activity after spinal injury unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 8, 16, 19]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [7, 8, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [17, 25, 26, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 16, 19]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [12, 26, 28]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [6, 9, 15, 23]}\n    ],\n    \"complexes\": [\n      \"MT2/5-HT2C receptor heteromer\",\n      \"5-HT2C receptor homodimer\",\n      \"Veli-3·CASK·Mint1 complex\"\n    ],\n    \"partners\": [\n      \"MTNR1B\",\n      \"DLG4\",\n      \"DLG3\",\n      \"CASK\",\n      \"APBA1\",\n      \"ADAR\",\n      \"ADAR1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}